BC
JUNO

Broadfin Capital’s Juno Therapeutics, Inc. JUNO Stock Holding History

Broadfin Capital’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-262,100
Closed -$7.83M – 58
2017
Q2 		$7.83M Buy
262,100
+86,400
+49% +$2.13M 0.95% 29
2017
Q1 		$3.9M Buy
+175,700
New +$3.77M 0.47% 43

Other funds holding JUNO

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital's JUNO Position: Q3 2017 in Review

Broadfin Capital sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2017, closing a stake of 262,100 shares — an estimated $7.83M sold.

Broadfin Capital first reported a position in JUNO in Q1 2017 and held it in 2 quarters. The position peaked at $7.83M in Q2 2017. 210 funds tracked by Wall St. Rank hold JUNO as of Q3 2017.

  • Broadfin Capital reported no remaining Juno Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Broadfin Capital sold 262,100 Juno Therapeutics, Inc. shares in Q3 2017, an estimated $7.83M.
  • Broadfin Capital first reported a position in Juno Therapeutics, Inc. in Q1 2017 and held it in 2 quarters.
  • Broadfin Capital's Juno Therapeutics, Inc. position peaked at $7.83M in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2017.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.